Esperion Therapeutics | ESPR - Interest Income


Esperion Therapeutics reported $-0.15 in Interest Income for its fiscal quarter ending in September of 2024.





Interest Income Change Date
AbbVie USD 59M 13M Dec/2025
Alnylam Pharmaceuticals USD 26.63M 2.05M Dec/2025
Amarin USD 3.37M 3.37M Dec/2024
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 19.21M 1.36M Dec/2025
CSL USD 18M 1000K Dec/2024
Cytokinetics USD 11.47M 1.22M Dec/2025
Daiichi Sankyo JPY 9.96B 230M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Esperion Therapeutics USD -0.15 0.18 Sep/2024
Geron USD 4.26M 392K Sep/2025
Heron Therapeutics USD 433K 277K Dec/2021
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
Merck USD 69M 27M Dec/2025
Moderna USD 70M 3M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 166M 166M Dec/2025
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 193.3M 18.2M Dec/2025
Sanofi EUR 33M 81M Dec/2025
Sarepta Therapeutics USD 8.38M 1.24M Sep/2025
United Therapeutics USD 46.4M 4.9M Sep/2025